It is expected that the inflation rate will reach 18% next year, and I believe that income stocks are particularly attractive for my investment portfolio. However, few companies will pay enough cash to fully offset the impact of rising prices. But every little bit helps, especially when this money can be used to purchase more stocks in a volatile market.
The performance records of two companies indicate that they believe they should continue to pay large salaries during this economic storm and increase expenses thereafter.
Very inexpensive.
Housing construction company Vistry (LSE: VTY), formerly known as Bovis Homes, has a forecasted dividend yield of 9.4%. This makes it one of the largest payers in the FTSE 250 index. In comparison, the overall return rate of the index is slightly below 3%.
The flagship stock tip service, Share Advisor, of Motley Fool UK has just released the top six stocks that their popular analysts believe are the best buys for investors currently. While timing isn't everything, their average return on previously selected stocks suggests that getting their best ideas early is worthwhile.
Learn more.
In my opinion, there are even more reasons to like this company. Vistry has a strong track record of increasing their annual dividends paid to shareholders. This indicates a healthy and well-managed business, which is exactly the kind of company I want to have in my investment portfolio.
Is it risky to buy from builders during an economic downturn? Well, it's true that the industry is cyclical. There are certainly signs that the real estate market is beginning to decline. The Royal Institution of Chartered Surveyors in the UK recently stated that there are fewer people looking to buy homes, which is starting to affect housing prices.
Despite this, in terms of valuation, Vistry stocks can now be purchased at a level close to their historical low point. Considering the company's reported outperformance in the first half of 2022, a P/E ratio of just 5 seems very cheap. It's no wonder the company has been buying back its own stocks recently.
Is the risk worth the reward here? I believe it might be, although to be on the safe side, I would not hesitate to diversify my investment portfolio.
Monster's Share of Revenue
On my list of potential income shares to purchase is British American Tobacco (LSE: BATS). Like Vistry, the FTSE 100 giant offers an attractive dividend flow. Currently, owning the stock would entitle me to a yield of 6.7%. This is certainly not as generous as the housebuilder mentioned earlier, but it's enough to help ease the pain of rising prices.
Similarly to Vistry, BATS also has an impressive record in improving payments (although not flawless). This is partially due to the consistency in its profits. The addictive nature of its products means that the company can be fairly certain of how many cigarette packs it will sell each year, at least compared to other consumer stocks.
Obviously, no dividend stream can be guaranteed. People also need to consider that tobacco consumption has been on a long-term downward trend and the industry is always susceptible to regulatory interference. Although I am highly focused on building long-term wealth, I do recognize that the stock price of British and American Tobacco has already risen by 25% in 2022.
Returning to the topic, the valuation of this stock is still at nine times the expected earnings. Therefore, even if the momentum does slow down in the coming months, it is difficult to believe that the stock price of British American Tobacco will collapse.
Why this £5 stock could soar: Are you searching for growth stocks in the UK? If so, get this free, no-obligation report while it's still available. You'll discover what we believe to be one of the fastest-growing stocks of the next decade...and this company's performance is indeed impressive. In 2019, it returned £150 million to its shareholders through buybacks and dividends. We believe its financials are as solid as anything we've seen.
Since 2016, the company has experienced a 31% increase in annual revenue. As of March 2020, one of its senior directors holds 25,000 shares valued at £90,259. The company's operating cash flow has also grown by 47%.
Translation: Statement
This article is compiled from third-party information and is intended solely for exchange and learning within the industry.
This article does not represent the views of 2FIRSTS, and 2FIRSTS cannot confirm the truthfulness or accuracy of the article's content. The compilation of this article is solely intended for industry-related exchange and research.
Due to limitations in translation ability, the compiled article may not fully express the same meaning as the original. Please refer to the original text for accuracy.
2FIRSTS maintains full alignment with the Chinese government regarding any domestic, Hong Kong, Macao, Taiwan, or foreign-related statements and positions.
The copyright of the compiled information belongs to the original media and author. If there is any infringement, please kindly contact us for removal.
Disclaimer
This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.
Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.
The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.
This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.
Copyright Notice
This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.
No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.
For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.
AI-Assisted Translation and Editing Notice
Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.
Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.
